

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 9, 2014

Xenetic Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Nevada

(State or other jurisdiction of incorporation)

333-178082

(Commission File Number)

45-2952962

(I.R.S. Employer Identification No.)

99 Hayden Avenue, Suite 230

Lexington MA 02421

(Address of principal executive offices)

Registrant's telephone number, including area code: 781-778-7720

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

SECTION 4- Matters Related to Accountants and Financial Statements

Item 4.01 Changes in Registrant's Certifying Accountant.

On April 9, 2014, L.L. Bradford & Company (the "Former Accountant") was dismissed as the Company's accountant. The Company has engaged Ernst and Young LLP, UK ("New Accountant") as its principal accountants effective April 9, 2014. The decision to change accountants was approved by the Company's board of directors.

The Former Accountant's audit reports on the financial statements of the Company for the fiscal years ended August 31, 2013 and 2012 contained no adverse opinion or disclaimer of opinion, nor were they qualified or modified as to uncertainty, audit scope or accounting principles, except that the audit reports on the financial statements of the Company for the fiscal years ended August 31, 2013 and 2012 contained an uncertainty about the Company's ability to continue as a going concern.

During the fiscal years ended August 31, 2013 and 2012, and through the interim period ended March 31, 2014, there were no "disagreements" (as such term is defined in Item 304 of Regulation S-K) with the Former Accountant on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedures, which disagreements if not resolved to the satisfaction of the Former Accountant would have caused them to make reference thereto in their reports on the financial statements for such periods.

During the fiscal years ended August 31, 2013 and 2012, and through the interim period ended March 31, 2014, there were the following "reportable events" (as such term is defined in Item 304 of Regulation S-K). As disclosed in Part I, Item 4 of the Company's Form 10-Q for the quarterly period ended November 30, 2013, the Company's management determined that the Company's internal controls over financial reporting were not effective as of the end of such period due to the existence of material weaknesses related to the following:

(i) inadequate segregation of duties and effective risk assessment; and

(ii) insufficient written policies and procedures for accounting and financial reporting with respect to the requirements and application of both United States generally accepted accounting principles and Securities and Exchange Commission guidelines.

Other than as disclosed above, there were no reportable events during the fiscal years ended August 31, 2013 and 2012, and through the interim period ended March 31, 2014. The Company's Board of Directors discussed the subject matter of each reportable event with the Former Accountant. The Company authorized the Former Accountant to respond fully and without limitation to all requests of the New Accountant concerning all matters related to the audited period by the Former Accountant, including with respect to the subject matter of each reportable event.

The material weaknesses described above relate to periods covered in periodic reports filed prior to the change in officers and directors that resulted from the reverse acquisition of Xenetic Biosciences PLC completed by the Company on January 23, 2014. Please refer to Current Report filed on Form 8-K on January 29, 2014 for information relating to the reverse acquisition including a summary of the change in officers and directors.

Prior to engaging the New Accountant, the Company did not consult with the New Accountant regarding either: (i) the application of accounting principles to a specified transaction, either contemplated or proposed, or the type of audit opinion that might be rendered on the Company's financial statements; or (ii) any matter that was the subject of a "disagreement" or a "reportable event" (as those terms are defined in Item 304 of Regulation S-K).

On April 9, 2014, the Company provided the Former Accountant with its disclosures in the Current Report on Form 8-K disclosing the dismissal of the Former Accountant and requested in writing that the Former Accountant furnish the Company with a letter addressed to the Securities and Exchange Commission stating whether or not they agree with such disclosures. The Former Accountant's response is filed as an exhibit to this Current Report on Form 8-K.

SECTION 9 – Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

Exhibit Description

No.

16.1 [Letter from L.L. Bradford & Company to the Securities and Exchange Commission](#)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Xenetic Biosciences, Inc.

/s/ M. Scott Maguire

M. Scott Maguire

Chief Executive Officer

Date: April 9, 2014



L.L. Bradford
Certified Public Accountants & Consultants

Office of the Chief Accountant
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549

RE: Xenetic Biosciences, Inc.
Commission file # 333-178082

We have received a copy of, and are in agreement with, the statements being made by Xenetic Biosciences, Inc. in Item 4.01 of its Form 8-K dated April 9, 2014 and captioned "Changes in Registrant's Certifying Accountant." We agree with all statements pertaining to us.

We hereby consent to the filing of this letter as an exhibit to the foregoing report on Form 8-K.

Sincerely:

/s/ L.L. Bradford & Company, LLC

Las Vegas, Nevada
April 9, 2014